Stay updated with breaking news from Probodyt Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- CX-904 initial Phase 1a dose escalation data anticipated in the 2nd half of 2024 - - IND application filed for conditionally activated EpCAM-directed ADC with Phase 1 initiation in EpCAM...
Operator: Good day and thank you for standing by. Welcome to the CytomX Therapeutics Third Quarter 2023 Financial Results. At this time, all participants are in a listen only-mode.
Operator: Good day and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
27.03.2023 - - Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 - - Bristol Myers ...